{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:56:50Z","timestamp":1782511010985,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012195"],"award-info":[{"award-number":["2022A1515012195"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhanjiang Science and Technology Plan Project","award":["2020A01022"],"award-info":[{"award-number":["2020A01022"]}]},{"name":"Zhanjiang Science and Technology Plan Project","award":["2022A01017"],"award-info":[{"award-number":["2022A01017"]}]},{"name":"Research Project of Traditional Chinese Medicine Bureau of Guangdong Province","award":["20211221"],"award-info":[{"award-number":["20211221"]}]},{"name":"Research Project of Traditional Chinese Medicine Bureau of Guangdong Province","award":["2022099"],"award-info":[{"award-number":["2022099"]}]},{"name":"Research Foundation for Advanced Talents of Affiliated Hospital of Guangdong Medical University","award":["20401Z20190003"],"award-info":[{"award-number":["20401Z20190003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00432-023-05584-3","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T07:02:32Z","timestamp":1704265352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis"],"prefix":"10.1007","volume":"150","author":[{"given":"Gaozhen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"5584_CR1","unstructured":"Administration NMPA. January 18, 2021 Drug approval document pending receipt information release [EB\/OL]. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20210118091934189.html. 18 Jan 2021\/1 May 2023."},{"issue":"22","key":"5584_CR2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"8","key":"5584_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw 20(8):866\u2013878","journal-title":"J Natl Compr Canc Netw"},{"issue":"10236","key":"5584_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395(10236):1547\u20131557","journal-title":"Lancet"},{"issue":"6371","key":"5584_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103","journal-title":"Science"},{"issue":"1","key":"5584_CR6","doi-asserted-by":"publisher","first-page":"1887551","DOI":"10.1080\/2162402X.2021.1887551","volume":"10","author":"L Guo","year":"2021","unstructured":"Guo L, Wang X, Wang S et al (2021) Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma. Oncoimmunology 10(1):1887551","journal-title":"Oncoimmunology"},{"key":"5584_CR7","doi-asserted-by":"crossref","first-page":"2050313x2093269","DOI":"10.1177\/2050313X20932694","volume":"8","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Hasegawa G, Ikeda Y et al (2020) Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: a case report. SAGE Open Med Case Rep 8:2050313x20932694","journal-title":"SAGE Open Med Case Rep"},{"issue":"8","key":"5584_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"4","key":"5584_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","volume":"78","author":"AM Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Karapetis CS et al (2020a) Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab. Eur Urol 78(4):540\u2013543","journal-title":"Eur Urol"},{"issue":"20","key":"5584_CR10","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","volume":"26","author":"AM Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Karapetis CS et al (2020b) Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res 26(20):5487\u20135493","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5584_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Keam SJ (2020) Tislelizumab: first approval. Drugs 80(6):617\u2013624","journal-title":"Drugs"},{"issue":"7698","key":"5584_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier L, Pruteanu M, Kuhn M et al (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555(7698):623\u2013628","journal-title":"Nature"},{"key":"5584_CR13","first-page":"154","volume":"26","author":"EF McCarthy","year":"2006","unstructured":"McCarthy EF (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 26:154\u2013158","journal-title":"Iowa Orthop J"},{"issue":"6","key":"5584_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/cancers12061449","volume":"12","author":"V Mollica","year":"2020","unstructured":"Mollica V, Rizzo A, Montironi R et al (2020) Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers (basel) 12(6):1449","journal-title":"Cancers (basel)"},{"issue":"12","key":"5584_CR15","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","volume":"7","author":"CA Nebhan","year":"2021","unstructured":"Nebhan CA, Cortellini A, Ma W et al (2021) Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol 7(12):1856\u20131861","journal-title":"JAMA Oncol"},{"issue":"1","key":"5584_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR et al (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19(1):51\u201364","journal-title":"Lancet Oncol"},{"issue":"9","key":"5584_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol 3(9):e172411","journal-title":"JAMA Oncol"},{"issue":"12","key":"5584_CR18","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D et al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 21(12):1574\u20131588","journal-title":"Lancet Oncol"},{"issue":"7","key":"5584_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22(7):931\u2013945","journal-title":"Lancet Oncol"},{"issue":"3","key":"5584_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E et al (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(3):244\u2013258","journal-title":"Ann Oncol"},{"issue":"1","key":"5584_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer 5(1):95","journal-title":"J Immunother Cancer"},{"issue":"2","key":"5584_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F et al (2019) Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 14(2):237\u2013244","journal-title":"J Thorac Oncol"},{"issue":"3","key":"5584_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective. Nat Rev Urol 11(3):153\u2013162","journal-title":"Nat Rev Urol"},{"issue":"1","key":"5584_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.euf.2021.01.003","volume":"8","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Mollica V, Massari F (2022) Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: a systematic review and meta-analysis. Eur Urol Focus 8(1):152\u2013159","journal-title":"Eur Urol Focus"},{"issue":"10031","key":"5584_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909\u20131920","journal-title":"Lancet"},{"issue":"7","key":"5584_CR26","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.21873\/anticanres.14409","volume":"40","author":"T Shioga","year":"2020","unstructured":"Shioga T, Kondo R, Ogasawara S et al (2020) Usefulness of tumor tissue biopsy for predicting the biological behavior of hepatocellular carcinoma. Anticancer Res 40(7):4105\u20134113","journal-title":"Anticancer Res"},{"key":"5584_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100870","volume":"80","author":"S Sivori","year":"2021","unstructured":"Sivori S, Pende D, Quatrini L et al (2021) NK cells and ILCs in tumor immunotherapy. Mol Aspects Med 80:100870","journal-title":"Mol Aspects Med"},{"key":"5584_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"5584_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"5584_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5584_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79(1):82\u2013104","journal-title":"Eur Urol"},{"issue":"5","key":"5584_CR32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"YL Wu","year":"2019","unstructured":"Wu YL, Lu S, Cheng Y et al (2019) Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol 14(5):867\u2013875","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5584_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","volume":"112","author":"D Ye","year":"2021","unstructured":"Ye D, Liu J, Zhou A et al (2021) Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci 112(1):305\u2013313","journal-title":"Cancer Sci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05584-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T09:04:29Z","timestamp":1710493469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5584"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05584-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflicts of interest was disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"5"}}